Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TAVIST ALLERGY/SINUS/HEADACHE is an oral combination tablet approved in 2001 for symptomatic relief of allergy, sinus, and headache symptoms. The product mechanism of action and specific pharmacologic class are not publicly detailed, but combination allergy/sinus/headache products typically contain antihistamines, decongestants, and/or analgesics. This is an over-the-counter or low-prescription small molecule indicated for common upper respiratory and pain symptoms.
With LOE approaching and moderate competitive pressure (30), the brand is likely in transition mode with focus shifting from growth maintenance to retention and transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TAVIST in its LOE phase offers limited growth trajectory but provides solid OTC commercial and brand management experience. Roles are concentrated in commercial and field-based positions with emphasis on market defense and channel management rather than innovation.
Worked on TAVIST ALLERGY/SINUS/HEADACHE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.